MEDICALSYSTEM(SZ:300439)2024-04-23 08:28Financial Performance - The company's revenue for Q1 2024 was CNY 481.51 million, a decrease of 1.91% compared to CNY 490.89 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 79.10 million, representing a year-on-year increase of 10.76% from CNY 71.41 million[4]. - The net profit after deducting non-recurring gains and losses was CNY 64.74 million, up 14.37% from CNY 56.61 million in the previous year[4]. - Total operating revenue for Q1 2024 was CNY 481.51 million, a decrease of 1.8% from CNY 490.89 million in Q1 2023[26]. - Net profit for Q1 2024 was CNY 78.05 million, an increase of 12.5% compared to CNY 69.65 million in Q1 2023[27]. - Earnings per share for Q1 2024 were CNY 0.21, up from CNY 0.19 in the same period last year[28]. Cash Flow and Assets - The net cash flow from operating activities was CNY 9.15 million, a significant decrease of 84.84% compared to CNY 60.35 million in the same period last year[4]. - The company's total assets at the end of the reporting period were CNY 3.44 billion, down 1.40% from CNY 3.49 billion at the end of the previous year[4]. - The company's cash and cash equivalents decreased to ¥809,335,968.51 from ¥958,881,876.13[22]. - The total number of shares after the stock incentive plan increased to 38,394,981.5 shares[20]. - The company reported a total current asset of ¥1,791,170,239.13, down from ¥1,899,165,542.09[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,366[16]. - The largest shareholder, Zou Bingde, holds 28.36% of shares, totaling 108,897,635 shares, with 11,000,000 shares pledged[16]. - The number of restricted shares held by Zou Bingde decreased to 81,673,226 shares after unlocking 14,362,493 shares[17]. Operating Costs and Expenses - Total operating costs decreased to CNY 412.34 million, down 4.1% from CNY 430.17 million in the previous year[26]. - Research and development expenses remained stable at CNY 38.30 million, compared to CNY 38.70 million in the previous year[26]. Investment and Financing Activities - The net cash flow from investing activities was -138,270,881.54, worsening from -16,019,336.91 in the previous period[31]. - Cash inflow from investing activities was 19,168,033.97, down 89.9% from 189,521,768.27 in the previous period[31]. - Cash outflow from financing activities was -20,432,329.74, improving from -72,062,091.34 in the previous period[31]. - Cash inflow from financing activities was 30,000,000.00, down 40.0% from 50,000,000.00 in the previous period[31]. Future Plans and Market Strategy - The company plans to enhance market share of self-produced products by focusing on in vitro diagnostic instruments and services[8]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[27]. Other Financial Metrics - The company experienced a 1070.02% increase in trading financial assets, reaching CNY 70.20 million due to the purchase of financial products during the reporting period[10]. - Government subsidies recognized during the period amounted to CNY 6.66 million, a 155.83% increase compared to CNY 2.60 million in the previous year[12]. - The company reported an increase in investment income to CNY 1.68 million, compared to a loss of CNY 2.93 million in Q1 2023[27]. - The company's cash flow from operating activities showed improvement, reflecting better management of working capital[29]. - The company's first quarter report was not audited[32].